Immuron (ASX:IMC) Pursues Strategic Partnership to Advance FDA IND-Cleared IMM-529

IMRN IMC

2 min read | July 06, 2026 11:48 AM AEST | By Sonal Goyal

Google News:

Immuron (ASX:IMC) Pursues Strategic Partnership to Advance FDA IND-Cleared IMM-529 — Image source: Company update

Recent News

Woodside (ASX:WDS): Why Are Santos and ASX 200 Energy Stocks Sliding?

SunRice (ASX:SGLLV): Why Is This ASX 300 Dividend Payout Turning Heads...

Coles (ASX:COL): Why Is the Supermarket Giant Facing a Regulatory Setb...

Why Is Superloop (ASX:SLC) Repricing The ASX Communication Story?

Make Kalkine Media
My Trusted Source

Highlights

Immuron has appointed Pullan Consulting to secure a strategic partner for the clinical development and commercialisation of IMM-529.

IMM-529 has received FDA IND application clearance, enabling a Phase 2 clinical trial for the prevention or treatment of Clostridioides difficile infection.

The Phase 2 study will evaluate IMM-529 alongside the standard of care in up to 60 patients with first-episode or recurrent CDI.

An independent market assessment estimated an annual revenue opportunity of approximately USD 400 million if IMM-529 is successfully commercialised.

Immuron Limited (ASX:IMC) (NASDAQ:IMRN) has appointed Pullan Consulting to support its business development efforts for IMM-529 , the company's investigational therapy targeting Clostridioides difficile infection (CDI) . The engagement is aimed at securing a strategic partner to advance the product through clinical development, regulatory approval and commercialisation.

Partnering Strategy Advances

Pullan Consulting is a life sciences advisory firm specialising in guiding biotechnology and pharmaceutical companies through partnering transactions. The consultancy will assist with partner identification, strategy development, transaction negotiations and execution.

Under a typical licensing arrangement, the partner would fund development, registration and commercialisation costs, while common licensing could include receipt of upfront payments, developmental milestone payments, and royalties on future product sales. The company noted that historical CDI licensing transactions have included upfront payments ranging from USD 1 million to USD 50 million, milestone payments of USD 25 million to USD 570 million, and mid- to high-single-digit royalty rates.

A development partnership for IMM-529 can be transformational for IMC.

IMC Shares Up

Following the update, IMC share price jumped 11.11% to trade at AUD 0.04 per share at the time of writing on 6 July 2026.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.